Eucrisa, Staquis(crisaborole)
Eucrisa, Staquis (crisaborole) is a small molecule pharmaceutical. Crisaborole was first approved as Eucrisa on 2016-12-14. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. It is known to target 3',5'-cyclic-AMP phosphodiesterase 4B, high affinity 3',5'-cyclic-AMP phosphodiesterase 7A, and dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Eucrisa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Crisaborole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EUCRISA | Anacor Pharmaceuticals | N-207695 RX | 2016-12-14 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CRISABOROLE, EUCRISA, ANACOR PHARMS INC | |||
| 2026-04-03 | D-191 | ||
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | HP_0011123 | L30.9 | 4 | 7 | 7 | 8 | 2 | 27 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 4 | 6 | 7 | 7 | 2 | 25 |
| Eczema | D004485 | HP_0000964 | L30.9 | 4 | 6 | 7 | 6 | 2 | 24 |
| Seborrheic dermatitis | D012628 | HP_0001051 | L21 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Caregiver burden | D000084802 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 3 | 4 | — | — | — | 7 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 1 | — | — | — | 1 |
| Alopecia | D000505 | HP_0002293 | L64 | — | 1 | — | — | — | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | 1 | — | — | — | 1 |
| Vitiligo | D014820 | EFO_0004208 | L80 | — | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Crisaborole |
| INN | crisaborole |
| Description | Crisaborole is a member of the class of benzoxaboroles that is 5-hydroxy-1,3-dihydro-2,1-benzoxaborole in which the phenolic hydrogen has been replaced by a 4-cyanophenyl group. A phosphodiesterase 4 inhibitor that is used for treatment of mild to moderate atopic dermatitis in children and adults. It has a role as a phosphodiesterase IV inhibitor, an antipsoriatic and a non-steroidal anti-inflammatory drug. It is a benzoxaborole, an aromatic ether and a nitrile. |
| Classification | Small molecule |
| Drug class | boroles, boron compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 906673-24-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL484785 |
| ChEBI ID | — |
| PubChem CID | 44591583 |
| DrugBank | DB05219 |
| UNII ID | Q2R47HGR7P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDE4B
PDE4B
PDE7A
PDE7A
Organism
Homo sapiens
Gene name
PDE4B
Gene synonyms
DPDE4
NCBI Gene ID
Protein name
3',5'-cyclic-AMP phosphodiesterase 4B; cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Protein synonyms
cAMP-specific phosphodiesterase 4B, DPDE4, dunce-like phosphodiesterase E4, PDE32, phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)
Uniprot ID
Mouse ortholog
Pde4b (18578)
3',5'-cyclic-AMP phosphodiesterase 4B (Q9QXI7)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Eucrisa – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 657 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,395 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use